ArticleBMC cancer2025
Risk factor analysis and predictive model development for secondary failure of platelet recovery following allogeneic hematopoietic stem cell transplantation.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Secondary failure of platelet recovery (SFPR) is a common complication following allogeneic hematopoietic stem cell transplantation (allo-HSCT), occurring in approximately 20% of cases, and is closely associated with poor patient prognosis. The purpose of this study is to analyze the risk factors associated with SFPR following allo-HSCT, develop a nomogram-based predictive model for SFPR, and validate its accuracy. Clinical data of patients who underwent allo-HSCT in the Department of Hematology at the First Hospital of Lanzhou University from January 2016 to December 2023 were collected. Variables with P < 0.05 in univariate analysis were included in a logistic multivariate stepwise regression to identify the final variables for the model. An SFPR nomogram prediction model was developed using R software and internally validated using the Bootstrap method. The accuracy of the prediction model was assessed through receiver operating characteristic(ROC) and calibration curves, while decision curve analysis evaluated its clinical predictive performance. Based on the body mass index(BMI), chromosome karyotype, transplant type, acute graft-versus-host disease(aGVHD) and post-transplant Interleukin-6(IL-6) and Procalcitonin(PCT), the predicted area under the ROC curve of SFPR is 0.778 (95% CI 0.697-0.858). The absolute error between the predicted risk of SFPR and the actual risk is 0.019. The SFPR nomogram prediction model developed in this study exhibits high accuracy and excellent predictive efficiency, thereby possessing significant clinical guidance value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.